All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2020; the latest 2022-04-04.
From the record
Royalty Pharma plc's filings since 2020 show 1 warning event: an auditor change (8-K item 4.01, the latest 2022-04-04) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+4.1% a year over 8 filed years; profitable in 8 of 8.
From the record
Royalty Pharma plc's 8 filed years say what it did: revenue went from $1.8 billion in fiscal 2018 to $2.4 billion in fiscal 2025, up 4.1% a year; it rose in 5 of 7 years; the deepest fall was 4% from fiscal 2023 to fiscal 2024; net income was positive in 8 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 8.8% a year. 21% of cash flow returned. Insiders: 74 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Royalty Pharma plc's diluted share count grew about 8.8% a year, and dividends and buybacks returned about 21% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 74 sales (74 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 8%: 8¢ of profit per shareholder dollar. Leverage 50%: owes 50¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Royalty Pharma plc earned about 8 cents of profit for every dollar of shareholders' money. Leverage: it owed about 50 cents per dollar of assets, and net share issuance: its share count shrank 5.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 25% of 315 in its family; net margin 32.4%.
From the record
Royalty Pharma plc's standing among 315 graded names in its industry family: revenue of $2.4 billion in fiscal 2025 ranks in the top 9% by size; a net margin of 32.4% ranks in the top 9%; revenue growth of 2.1% a year over the last 3 filed years ranks in the bottom 41% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 35% of 315 in its family for leadership; chief executive since 2020.
From the record
Royalty Pharma plc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Legorreta, Pablo G. (CEO, Chairman of the Board, as filed), filing under that title since 2020-06-15, 6.4 years (top 34% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.3 years (top 36%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 42% of 273 in its family for room to expand.
From the record
Royalty Pharma plc's room to grow, from the newest filed statements (fiscal 2025): cash of $619 million against debt of $8.6 billion leaves -40.5% of its assets as net cash, bottom 2% of its family; cash from operations less capital spending is 104.7% of revenue (top 2%); research spending of 19% of revenue (bottom 24%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 39% of 306 in its family for growth drivers.
From the record
Royalty Pharma plc's growth drivers, from the filed years to fiscal 2025: revenue grew 2.1% a year over the last three filed years against 4.1% over all 8, slowing (bottom 49% of its family); the newest year grew 5.1% (bottom 46%); research spending grew 36.6% a year (top 12%) (its annual reports). Royalty Pharma plc reported 2 product lines in fiscal 2025: Financial Royalty Assets at $2.3 billion (95%), Royalty Income Other at $117 million (5%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 50% of 233 in its family for expectations against reality.
From the record
Royalty Pharma plc's newest year against its own record: revenue of $2.4 billion in fiscal 2025 came in 4.5% above the $2.3 billion its prior three years' pace pointed to (top 39% of its family); net income of $771 million against a prior three-year average of $679 million (bottom 49%); a net margin of 32.4% against 29.4% before (bottom 41%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made